Aftermarket MindMed (NEO:MMED) announced they entered into a clinical trial agreement with Maastricht University to undertake a Phase 2a clinical trial for lysergic acid diethylamide (LSD) in adult patients with Attention Deficit Hyperactivity Disorder (ADHD).
As per the agreement, Maastricht University will provide facilities and personnel for the Phase 2a Proof of Concept Clinical Trial for MindMed’s multicentre, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of low dose LSD as treatment for ADHD in adults.
The company will now advance to an LSD microdosing program with both Dr Kuypers and the University Hospital Basel’s Liechti Lab. They are currently in the regulatory ethics submission process in the Netherlands and plans to begin the Phase 2a clinical trial by the end of the year. In order to create a portfolio of clinical trials studying the use of sub-perceptual amounts of psychedelic substances for medical purposes the company established a microdosing division.
MindMed stock closed today up 3c to 60c.
Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
